UNSPSC 51283001: Pirlimycin

This classification denotes a lincosamide antibiotic with the molecular formula C17H31ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LM19JT6G5K, chemically known as l-threo-alpha-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((4-ethyl-2-piperidinyl)carbonyl)amino)-1-thio-, monohydrochloride, (2s-cis)- but generally known as pirlimycin, which bears US NIH Compound Identifier 115329.

UNSPSC 51283001 Pirlimycin is a Commodity code that in recent state and local procurement activity encompasses a broader range of pharmaceutical and medical supply products than the code name alone suggests—specifically naloxone, safe drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products distributed through state purchasing cooperatives. State and local buying under this code spans county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances. Work being solicited includes direct product procurement (naloxone and drug deactivation systems for community health initiatives), emergency medical supplies for first responder use, and establishment of statewide pharmaceutical supply contracts through authorized wholesalers with specific National Drug Codes and pricing structures.

Recent activity concentrates in Florida and Minnesota, with exploratory procurement underway in Texas. The Seminole County, Florida, purchasing office issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to the county community health building. The City of Tampa issued IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a $700,000 estimated contract value and a March 13, 2026 deadline. The Minnesota Department of Administration's Office of State Procurement, administering the multistate MMCAP cooperative, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs as a preliminary market intelligence phase preceding formal competitive solicitation.